Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA’s Social Media Guidance Gives Firms A Pass On User-Generated Content

Executive Summary

The draft guidance outlines substantial reporting requirements for websites that firms control and for content on third-party sites – as well as saying when FDA intends to use enforcement discretion.

Advertisement

Related Content

Will #Cures2015 Fix Twitter Promotion?
FDA Guidance On Health Care Economic Data Is Coming In 2015
Social Media Marketing: FDA’s Old-Time Approach May Turn Industry Away
FDA Formula Allows Tweets About Products Without Excessive Risks
FDA’s Twitter Formula Allows Tweets About Products Without Excessive Risks
Rx Drug Promotion Risks: Value Claims, Getting Close To Patients
Warning For Facebook “Likes” Reflects FDA Social Media Approach
Off-Label Use Discussions Should Stay Off-line, FDA Draft Guidance Says
Enforcement In Brief
Internet Promotions Must Be Redesigned After FDA Cites Sponsored Web Links

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS055869

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel